The civic question
Does it have to remain this way?
Could public tools be repurposed—from punishment to care, from secrecy to knowledge, and from uncontrolled supply to accountable control?
The paper argues that people make safer and more legitimate decisions when scientific evidence, lived experience, product testing, professional observation and individual values can be examined together.
Its position is rights-based but not risk-blind. An adult with decision-making capacity should have the greatest possible control over what enters their body, supported by full and honest information. That does not require a clinician to call an unknown product safe, excuse impaired driving, or treat one experience as universal truth.
Science and lived experience
A signal is not proof.
It is still information.
Patient reports can reveal pain, withdrawal, cognitive changes, stigma and failures of communication that trials may not measure well. They can identify possible signals and questions worth investigating.
They cannot establish frequency or causation alone. The stronger inquiry combines stories with laboratory testing, clinical records, pharmacovigilance, qualitative research and population evidence while preserving the limits of each.
What the paper proposes
Transformation,
not abolition.
- 01
Treat informed refusal, supported tapering and reasonable alternatives as ordinary parts of care.
- 02
Use non-judgmental language and distinguish physical dependence, addiction, pain relief, pleasure, coping and experimentation.
- 03
Assess drug checking, supervised settings, naloxone access and honest interaction information as health measures.
- 04
Publish ownership, payments, prices, formularies, evidence submissions and conflicts so influence can be examined.
- 05
Build research with patients, people who use drugs, pharmacists, paramedics and other frontline workers while protecting confidentiality.
- 06
Pilot regulated access only with standardised products, privacy safeguards, independent evaluation and continued protection of other people.
Complete scope
What the source paper contains
The framing page is an orientation, not a replacement. Download the supplied source to read its full argument, tables, figures, 51 references and two appendices.
- 01The situation I can see and the question it creates
- 02Drugs language and moral categories
- 03Science and lived experience
- 04Consent, refusal and patient choice
- 05Prescribed dependence and preventable harm
- 06Harm reduction and regulated care
- 07Frontline and paramedic knowledge
- 08Access, control, money and commercial power
- 09Cannabis and ketamine case studies
- 10Police time, prison space and public money
- 11A regulated access model
- 12A practical method for questioning treatment
- 13Sources for alternative and patient perspectives
- 14Reading experience reports responsibly
- 15Principles for humane drug policy
Method and limits
The paper shows its workings.
Official guidance, law, published research, laboratory services and documented public statistics are cited directly.
Patient and frontline accounts are treated as possible signals whose identity, timing, combinations and alternative explanations must be checked.
Police-time, prison-capacity and revenue calculations are transparent scenarios built from stated assumptions—not official forecasts or promised cash savings.
The regulated-access model is a policy design for testing. It does not claim that every drug becomes harmless or that every illicit market disappears.
Authoritative source
Read the complete discussion draft.
Both files are the unchanged documents supplied for publication. The PDF is the stable reading copy; the DOCX preserves an editable version.